Nemaura Medical (NMRD) 8-K Regulation FD Disclosure

Nemaura Medical Inc.

(NMRD)

ROTH Conference Presentation

March 11^th2015

1

Presentation Overview

2

Our Background

•

Founded in January 2009 by Dr D F Chowdhury, the majority shareholder and the CEO

•

Biotech diagnostics research focused, headquarters in United Kingdom

•

Research facilities location at Science Park, Loughborough University, UK

•

Proprietary technology on transdermal (works through the skin) applications

•

diagnostic technologies

•

drug delivery technologies

•

Owned a family of related patents across various continents

•

Monitor commercialization process through sub-contracting to expert production and marketing vendors

•

Trading on NASDAQ OTC BB ticker: NMRD

3

Key events

Date

Event

2009-14 2012 2014 2014 2015 2015

Cumulatively received over $2M in discretionary grants from UK government bodies Successfully completed proof of concept studies in human volunteers Secured UK licensee for glucose monitoring – with $1.65m upfront Received trading symbol for OTC BB Successfully completed clinical study in Type 1 and 2 diabetics Awaiting approval for CE kite mark allowing sales of first product in Europe, HK and Saudi Arabia

4

Our Core Business

Platform technology developed for Drug Delivery and Diagnostic Applications.

Current Focus: (Diagnostic Applications)

Non-invasive, continuous and painless monitoring of analyte / molecules. For example: glucose, lactate, prescription drugs.

Future Focus: (Drug Delivery)

Drug Delivery complementing diagnostic application.

For example, non invasive insulin delivery working in tandem with non invasive continuous glucose monitoring.

5

Management Overview

Core Team of 21 People consisting of:

•

5 Board Members

•

4 Science Advisory Team Members

•

12 Technical Team Members

CEO: Dr D F Chowdhury:Microsystems and Nanotechnology from Cranfield University and PhD from the University of Oxford in nano-drug delivery; over 18 patents pending/granted.

CFO: K Farrar:MChem from University of Oxford, Chartered Accountant, 10 years with KPMG.

CTO: Prof. K. Khan:Launched over 60 products during his career in the Pharmaceutical Industry.

Medical Device & Regulatory Director: R Carson– A Pharmacologist with 20+ years experience in medical device design and registration in Europe and US.

6

Government Support

Recipient of over $2m in several separate UK government grants awarded under independent competitive tendering process.

Grants awarded by UK Government Technology Strategy Board. Independent government assessor quoted:

‘The product could be a game changing technology’.

7

Our Patents

Patents granted:

Region	Purpose	Expires
EU, China, Hong Kong	Patches patent for reverse iontophoresis:  Device patent describing construction of patches Device patent for extracting glucose from skin non- invasively.	June 2028
Europe, USA, Canada	Method patent for measuring relative level of two substances Method patent to avoid finger prick to calibrate device	June 2021

Patents submitted:

Region	Purpose	Date applied/ Expiry
Australia, Brazil, Canada, India, Japan,	Patch patent for Reverse Iontophoresis Device patent for construction of patches Device patent for extracting glucose non-invasively.	June 2008/    June 2028
USA, Canada, Brazil, Europe, Japan, China, India, Australia, Qatar, United Arab Emirates	Method patent for cumulative measurement of analyte Algorithm patent for measurement of analyte without long delays	May 2012/ May 2032

8

sugarBEAT™ Product

Our first commercialized product

sugarBEAT™

9

sugarBEAT™ Product

sugarBEAT™consists of three parts;

1.

a disposable patch(“Patch”)

2.

bluetooth enabled device(“Device”)

3.

smart phone app(“App”)

To usesugarBEAT™:

1.

Affix Patch to arm

2.

Connect Patch to adjacently worn Device via thin wire

3.

Device transmits real time data to App

4.

App can send data online to remote health care team

sugarBEAT™provides up to 4 readings an hour for 12 hours or more.

10

sugarBEAT™ Product – How it Works

11

sugarBEAT™ Product - Clinical Need

•

Diabetics suffer from unstable blood glucose levels

•

Diabetics therefore need toconstantly monitorglucose levels.

•

Currently the most common monitoring method involves:

•

Extracting a drop of blood (droplet) bypiercingthe skin (finger pricking) several times a day.

•

This droplet is placed onto a test strip to provide a glucose reading.

•

Other methods requireintrusive insertioninto subcutaneous tissue.

•

The test strip market alone iscurrently generating over $10 Billion sales per annum.

•

There ishuge demandforour non – intrusive and continuous monitoring method, which isconvenient, timelyandpainless.

•

Our method will also providesubstantial savings to diabetic patients.

12

•

sugarBEAT™ Product – Image of Device

13

sugarBEAT™ Product – Illustration of AP

14

Our Technology - sugarBEAT™

Technical basis:

•

Works by passing a mild current across the skin that is barely perceptible, or non-perceptible.

•

This current pulls the glucose out of interstitial fluid, which is found just below the top layer of skin, into a reservoir in the patch.

•

The patch contains a sensor, which measures the amount of glucose analyzed.

•

An algorithm within the device converts this reading to a glucose concentration value.

•

This reading is displayed on the device with sound and / or buzzer alert

15

Our Clinical Trials for sugarBEAT™

Clinical Data in Type I and II Diabetics:
Interim data accuracy in Clark Error Zones A+B >85%
20 subjects/60 patient day studies tested in 1,179 paired data points*
Note:Interim data presented in adjacent chart. Data validation currently in progress.

*Hemocue vs CGM

16

Regulatory Approval for sugarBEAT™

CE mark applied for which will permit sales in:

•

European Union countries

•

Saudi Arabia

•

Honk Kong

•

US and Japan Regulatory Approval to be sought 2016 onwards

17

Target Market Analysis for sugarBEAT™ Product

18

Why sugarBEAT™ better than competition?

Competitors using invasive continuous technology have the following cons:

•

Cost – much more expensive

•

User market – mostly only suitable for type 1 diabetics which are only 10% of total diabetic market

•

Comfort – all require the continuous insertion of a measuring device into the body tissue which has high degree of user discomfort

19

Why sugarBEAT™ better than competition?

Competitors using finger prick technology suffer following cons:

•

Finger prick is painful

•

Finger prick is not continuous – most users only finger prick 1-2 times a day even though WHO recommends 5-7 times a day

20

Commercialization Process for sugarBEAT™

•

Manufacturing Development of Devices – Q2-Q4 2015

•

Manufacturing Development of Patches – Q2-Q4 2015

•

Mobile App development and launch – Q4 2015

•

Product Launch in HK, Saudi Arabia – Q4 2015

•

Product Launch in UK – Q1 2016

21

Production and Operations for sugarBEAT™

We are dedicated R&D company.

All manufacture and sales therefore subcontracted to expert partners.

Preferred partners selected for:

•

Device manufacture

•

Sensor Manufacture

•

Patch Manufacture

•

Electronics

22

Sales & Distribution for sugarBEAT™

Criteria for selecting specialist partners: (partner already selected for UK)

23

Financial Forcasts for sugarBEAT™

In Million ($ US Dollar)/ Year to March 31,	2016	2017	2018	2019	2020
Revenue	10	85	270	461	694
Cost of sales	7	42	136	244	366
Gross profits	3	43	134	217	328
Total expenses	10	15	14	24	29
Income before taxation	(7)	28	120	193	299
Taxation	- -	6	24	38	59
Net income	(7)	22	96	155	240

24

Our Future Potential – Drug Delivery

Works by inverting technology so drugs delivered non-invasively into skin via a reservoir in the patch.

Technology suitable for:

•

Programmed drug delivery

•

On-demand drug delivery

•

Chrono-therapeutic drug delivery

•

Closed loop diagnostic and drug delivery

•

Basal Insulin expected to be first product chosen

25

Contacts

Dr D F Chowdhury Nemaura Medical Inc. Holywell Park Ashby Road Loughborough Leics, LE11 3AQ UK
Tel: +44 1509 222 912
Email: faz.chowdhury@nemaura.co. uk
www.nemauramedical.com Bashir Timol Nemaura Medical Inc. Holywell Park Ashby Road Loughborough Leics, LE11 3AQ UK
Tel: +44 1509 222 912
Email: bashir.timol@nemaura.co.uk

26